80 results about "Infection induced" patented technology

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention belongs to the technical field of biology, and discloses application of wogonin in resisting siniperca chuatsi and frog iridovirus, the wogonin can effectively inhibit over-generation of ROS caused by MRV virus infection, and oxidative stress damage of host cells is relieved in a dose-dependent mode. The wogonin can be used for preventing and treating the siniperca chuatsi and frog iridovirus, the high expression state of a proinflammatory gene can be reduced, intestinal tissue damage induced by MRV infection can be relieved, proliferation of MRV in the micropterus salmoides is effectively inhibited, the MRV challenge survival rate of the micropterus salmoides is increased, a basis is provided for preparing a product for resisting the siniperca chuatsi and frog iridovirus from wogonin, and the wogonin has important application value. Meanwhile, the invention also discloses a medicine, a fish feed and a fish feed additive of the wogonin.

The invention belongs to the technical field of biological medicines, and particularly relates to application of UH15-38 in preparation of a medicine for preventing and treating PEDV-PoRVA co-infection. According to the invention, a PEDV and PoRVA co-infected piglet model is systematically established for the first time, a high-throughput transcriptomics means is combined, an enhancement mechanism of co-infection on host pathogenicity is deeply analyzed from an immune regulation level, and based on the mechanism, UH15-38 is found to be capable of effectively treating PEDV and PoRVA co-infected piglets. Experimental data show that the UH15-38 remarkably relieves clinical diarrhea symptoms caused by co-infection, reduces the copy number of PoRVA and PEDV viruses, effectively inhibits duplication of the viruses in intestinal tracts, remarkably reduces the expression levels of IL-1beta and p-MLKL in jejunum tissues, and reduces necrotic apoptosis and inflammatory response. The UH15-38 can provide a new application value for the treatment of the porcine viral diarrhea.

It discloses a method for the treatment of disease caused by HIV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound (1) or a pharmaceutically acceptable salt thereof.

The invention discloses a novel application of tripterine in anti-inflammatory treatment of severe influenza A virus infection. The invention relates to a novel application of tripterine in anti-inflammatory treatment of severe influenza A virus infection, and discloses that tripterine can effectively inhibit inflammatory response caused by severe influenza A virus infection and reduce pathological injury of lungs without affecting antiviral immune response.

The application discloses the use of carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone in the prevention and treatment of candida infection, belonging to the technical field of candida infection prevention and treatment. Carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone is used as the only active ingredient for preparing a medicine for preventing or treating diseases caused by candida infection, wherein the candida is candida albicans and / or candida auris; or it is used for preparing a bacteriostatic and / or bactericidal product of candida, wherein the candida is candida albicans and / or candida auris. FCCP shows good inhibition of strain growth, good inhibition of biofilm effect and good mitochondria breaking effect in the antibacterial experiments of various candida (wild type candida albicans, drug resistant candida albicans and drug resistant candida auris). Thus, a new treatment drug for candida albicans and candida auris infection is provided.

The invention belongs to the technical field of biological medicine, and particularly relates to a monoclonal antibody for resisting novel coronavirus and application of the monoclonal antibody. In particular, the present invention relates to monoclonal antibodies against novel coronaviruses, as well as compositions (e.g., diagnostic and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibody of the invention can be used for diagnosing, preventing and / or treating infection of novel coronavirus and / or diseases caused by the infection.

The invention provides application of periplocin in preparation of anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drugs, and belongs to the technical field of antiviral drugs. Experimental results show that periplocin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the periplocin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and / or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and / or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.

This invention relates to a fusion protein, immunogenic composition, and recombinant vaccine for the prevention of Escherichia coli infection. The invention provides a novel target, PstS, for Escherichia coli vaccine design. Starting from the tertiary structure of PstS and YidR proteins, and combining immunoepitaxes, stable domains of PstS and YidR proteins and their variants are ultimately screened, leading to the construction of a fusion protein. Both the PstS monoantigen protein molecule and the PstS-YidR fusion protein molecule of this invention exhibit good immunogenicity, can reduce tissue lesions caused by Escherichia coli infection, and demonstrate high efficacy in preventing Escherichia coli infection, showing broad application prospects.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The invention belongs to the technical field of bioengineering, and particularly provides application of a JNK inhibitor in preparation of drugs for preventing and / or relieving and / or treating pulmonary tuberculosis aiming at the problem that whether the existing JNK inhibitor SP600125 can inhibit BNIP3-mediated mitochondrial autophagy and further exert the ROS bactericidal effect is unknown. And the JNK inhibitor is an SP600125 JNK inhibitor. The JNK inhibitor is used for inhibiting mitochondrial autophagy in the BCG infected macrophages. The JNK inhibitor reduces the up-regulation of BNIP3 and LC3B caused by BCG infection. It is found through the application that when the concentration of the JNK inhibitor reaches 15 umol / L, remarkable cytotoxicity begins to appear, and compared with a control group, the cell survival rate is remarkably decreased. The SP600125 can be used for inhibiting mitochondrial autophagy and down-regulating the expression of BNIP3 and LC3B. Inhibition of JNK expression can inhibit survival of Mtb in RAW264.7 macrophages, and a new thought and direction are provided for treatment of tuberculosis.

The invention relates to the technical field of materials for preventing and treating local infection, in particular to drug-loaded composite nanoparticles as well as a preparation method and application thereof. The drug-loaded composite nanoparticles provided by the invention comprise hollow polydopamine grafted with vancomycin and lipoic acid-quaternary ammonium salt ionic liquid loaded into a cavity of the hollow polydopamine. In the invention, the HPDA nanoparticles have a hollow structure, and the structure provides sufficient space for loading of drug molecules. The lipoic acid-quaternary ammonium salt ionic liquid can generate heat energy under the microwave heat effect, and bacteria are effectively killed. Besides, under microwave stimulation, the lipoic acid-quaternary ammonium salt ionic liquid not only can enhance the sterilization effect, but also can reduce inflammatory response caused by bacterial infection through the synergistic effect of microwave heat effect and chemical sterilization.

The present invention belongs to the technical field of aspergillosis treatment, and specifically discloses the use of carbonyl cyanide-4-trifluoromethoxyphenylhydrazone in the prevention and treatment of Aspergillus fumigatus infection, that is, using it as the sole active ingredient in the preparation of a drug for preventing or treating diseases caused by Aspergillus fumigatus infection, or for the preparation of an antibacterial and / or bactericidal product for Aspergillus fumigatus. The present invention first discovered that carbonyl cyanide-4-trifluoromethoxyphenylhydrazone has a significant inhibitory effect on both wild-type and drug-resistant strains of the human pathogenic fungus Aspergillus fumigatus, and can inhibit its colony growth, hyphal growth, and conidia formation, thereby providing a new therapeutic drug for Aspergillus fumigatus infection. At the same time, it solves the problem of antibiotic resistance that plagues the clinical treatment of Aspergillus fumigatus infection, and can circumvent the disadvantage that antibiotics are prone to drug resistance.

The invention provides an application of OICR-9429 or a pharmaceutically acceptable salt thereof in preparation of a product for improving senescence indications. The OICR-9429 provided by the invention shows multiple beneficial technical effects in the aspect of improving senescence-related indications, not only can effectively relieve inflammatory response caused by pyroptosis in the senescence process, but also can improve the immune function and anti-infection ability of senescence organisms. The OICR-9429 also has a remarkable treatment effect on sepsis, the increase of the inflammation level caused by infection is inhibited, the survival rate of old patients is increased, and the prognosis is improved. Long-term intervention of the OICR-9429 can continuously relieve the chronic inflammation state of an aging body, increase the muscle mass, enhance the exercise ability, prolong the life and reduce various lesions accompanied by aging. The invention lays a foundation for developing products for comprehensively intervening aging and related function decline, and has important application value in the aspect of improving the life quality of old people.

The present invention refers to the veterinary field. Particularly, it refers to a strain of Glaesserella parasuis, or a composition comprising thereof. Preferably, the strain or composition is for use in a method for the prevention and / or treatment of Glässer's disease or a condition caused by infection with a virulent Glaesserella parasuis strain. It also refers to a device suitable for administering a medicine to porcine animals characterized in that it comprises a non-virulent live strain of Glaesserella parasuis.

The application discloses an oil and fat composition for resisting porcine enterovirus infection and application thereof. The oil and fat composition comprises at least two of glyceryl monopentanoate, glyceryl monolinoleate and glyceryl monomyristate. The oil and fat composition can further comprise anhydrous ethanol, propylene glycol, dimethyl sulfoxide, edible oil, Tween 80, lactose, mannitol, soluble starch, water and other auxiliary materials for preparing oil and fat composition preparations. The oil and fat composition can inhibit enterovirus through multiple channels and multiple levels, and improve the antiviral effect. Adding the oil and fat composition in the feed of pigs can not only improve the antiviral ability, but also reduce the inflammatory reaction caused by pathogenic infection through the anti-inflammatory and immune regulation effects, effectively prevent and treat the infection of porcine enterovirus diarrhea, and thus reduce the incidence of porcine enterovirus diarrhea and the mortality of pigs with the disease. The oil and fat composition can be used for preparing a medicine or a feed additive for treating and preventing porcine enterovirus diarrhea.

The application provides a combined medicine containing a nitrothiazolyl acid amide derivative and application thereof, and belongs to the field of chemical medicines. The combined medicine contains component A and component B which are administered simultaneously or separately and have the same or different specifications, and a pharmaceutically acceptable carrier. The component A is a nitrothiazolyl acid amide derivative shown in formula I, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The component B is a fatty acid, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The combined medicine is used for preventing and / or treating infections and related diseases. The combined medicine can produce a synergistic effect, is used for treating viral, bacterial and parasitic infections and related diseases, and has a good treatment effect. Meanwhile, the combined medicine has good safety in use, provides a new choice for clinically treating infections and related diseases caused by infections, and has a good application prospect.

The present invention provides a rapid method using whole blood samples for determining the severity of COVID-19 disease arising from SARS-CoV-2 infection and monitoring progression and treatment of t

The invention discloses an application of a serum protein biomarker in preparation of an auxiliary evaluation reagent related to feline calicivirus infection. The biomarker is long-chain acyl coenzyme A synthetase 4 (ACSL4) or calcium binding protein S100A2. When the expression level of the ACSL4 protein in the serum of the to-be-detected cat is obviously increased relative to the expression level in the control serum of a healthy cat, the FCV infection induced lung injury is indicated; when the expression level of the S100A2 protein in the serum of the to-be-detected cat is obviously reduced relative to the expression level in the control serum of the healthy cat, the FCV infection related oral lesion prognosis is poor. The serum ACSL4 and S100A2 can be used as specific biomarkers of FCV infection, so that the problem of high detection false negative rate caused by high virus variation is solved, the diagnosis accuracy is remarkably improved, and quantitative evaluation on clinical prognosis of FCV infection is realized.

This invention belongs to the field of antibacterial chemical drug technology, specifically relating to a resorcinol compound, its preparation method, and its application. Using resorcinol as the parent core, this invention introduces acyl side chains with different substituents at the 2 and 4 positions of the benzene ring of resorcinol, designing and synthesizing resorcinol compounds with novel structures. Experiments have demonstrated that these resorcinol compounds exhibit significant antibacterial activity against Gram-positive bacteria. Some of these compounds achieve antibacterial effects that are 2 to 4 times stronger than the positive control drug vancomycin. They can be used as novel antibacterial drugs to treat diseases caused by drug-resistant bacteria, possessing significant medicinal value and broad application prospects.

Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and / or treating RSV infections or diseases and / or symptoms caused by RSV infections by means of using the fusion protein, nucleic acid molecule and vaccine.

Methods for treating or preventing ulcers caused by Epidermolysis Bullosa (“EB”), EGFR inhibitor-induced skin toxicities, lesions caused by Hailey-Hailey Disease (“HHD”), Buruli Ulcers, and SARS-CoV-2 infections, by topically applying a hypotonic, acid oxidizing solution containing hypochlorous acid (HClO) to the affected area.

A vaccine comprising a live avirulent strain of bacteria or an immunogenic composition that comprises a live avirulent strain of bacteria, wherein the bacteria is cured of plasmids and / or transposons that contain AMR genes, and a non-conjugative synthetic curing plasmid that cures plasmids and / or transposons that contain AMR genes from such bacteria. A method for producing the live avirulent strain of bacteria or an immunogenic composition that comprises a live avirulent strain of bacteria; a method for treating, preventing, or reducing the severity, duration, or incidence of clinical signs, of a virulent bacterial infection; and a method for preventing, or reducing the risk or incidence of transference of AMR genes are also disclosed.

To provide compositions for treating and / or preventing RSV infection-induced acute respiratory tract illness including pneumonia and bronchitis.SOLUTION: The disclosure provides a composition for inducing immune response to RSV, the composition comprising an RNA molecule comprising at least one open reading frame encoding a respiratory syncytial virus (RSV) fusion protein F (F) polypeptide. The disclosure further relates to a composition comprising the RNA molecule formulated in a lipid nanoparticle (RNA-LNP). The disclosure further relates to the use of the RNA molecule, RNA-LNP, and composition for treating and / or preventing RSV infection-induced acute respiratory tract illness including pneumonia and bronchitis.SELECTED DRAWING: None

The invention discloses an application of OTX008 in the treatment of HSV-1 virus infection. The application verifies that the galectin-1 selective inhibitor OTX008 can remarkably promote activation of an I-type interferon signal channel of a host after virus infection by constructing a mouse model infected by an HSV-1 virus; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows an immunopotentiation effect in mouse peritoneal macrophages. Therefore, the OTX008 disclosed by the invention can be used for promoting the function of an innate immune cell and inhibiting the replication of the HSV-1 virus in the cell; an immune escape strategy of the HSV-1 virus is cracked; the defect of high drug resistance of the traditional HSV-1 virus treatment drug is overcome to a certain extent; according to the application, a new host drug target spot is found, and a good clinical application prospect in resisting HSV-1 virus infection is shown.

The invention discloses application of an iron chelating agent in treatment of HSV-1 and VSV virus infection. By constructing a mouse model infected by HSV-1 and VSV viruses, it is verified that the iron chelating agent can significantly promote activation of an I-type interferon signal channel of a host after virus infection; virus replication in various tissues can be inhibited, and secretion of antiviral cell factors can be promoted; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows a consistent immunopotentiation effect in mouse and human immune cells; the iron chelating agent is selected from any one or a combination of more of deferoxamine mesylate, deferiprone and ciclopirox. The iron chelating agent provided by the invention does not depend on virus TK / DNApol, overcomes the defect of high drug resistance of traditional HSV-1 and VSV virus treatment drugs to a certain extent, and has good clinical application prospects and application values.

The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein / hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.

Inclusion complex comprising an active pharmaceutical ingredient which is a P2X7 inhibitor receptor antagonist (e.g. lidocaine hydrochloride, articaine) and a cyclodextrin (e.g. HP beta cyclodextrin) for use in the treatment of an autoimmune disease or a condition in which an immune response caused by a disease or infection causes hyperinflammation (e.g. Long COVID) wherein the inclusion complex is presented for administration to the lymphoid system. A base (e.g. sodium bicarbonate) may be further included in the inclusion complex. Inclusion complex may be administered intra- or sub-dermal or subcutaneously, e.g. by infusion pump or pen injector. Also claimed is a formulation comprising an inclusion complex, said complex comprising lidocaine.HCl or articaine.HCl, hydroxypropylated β-CD, a pH modifier and water wherein the pH is 5-7.4 and the ratio and concentration of components is further limited. Said formulation may have a shelf life of at least 32 weeks based on accelerated testing at 60 °C.